DIACCURATE
DIACCURATE, a French biotechnology company that develops sole-in-class therapeutics in immunotherapy, oncology and infectiology today announced the formation of its Scientific Advisory Board (SAB). Composed of 6 independent world-leading experts in the fields of basic and translational immunology, lipid metabolism, oncology and immunotherapy DIACCURATE’s SAB is chaired by Professor Tasuku HONJO, Kyoto University’s Institute for Advanced Study (KUIAS), awarded by the 2018 NOBEL PRIZE in Physiology or Medicine for his discovery of "immune checkpoint inhibitors", a key step in the history of cancerology.
Dr. Dominique BRIDON, CEO of DIACCURATE , commented: "We feel honored to have gathered this world-renowned group of experts in our newly formed Scientific Advisory Board around Prof. Jacques THÈZE, CSO and Scientific co-Founder of DIACCURATE”. He added: “We look forward to building on their exceptional knowledge and complementary experience in immunology, immunotherapy and oncology to progress our highly original and ambitious pipeline towards the clinic.”
“Cancer treatment has seen a revolution in immunotherapy. Extensive research to which my lab has contributed has brought to light the importance of cytotoxic CD8 T cells in the antitumor immune response, giving rise to current immune checkpoint inhibitors. But the role of CD4 T cells in this response had so far remained overlooked”, said Prof. Tasuku HONJO, Deputy Director-General of KUIAS and Chairman of DIACCURATE’s SAB . He explained: “Recent findings have demonstrated the key contribution of CD4 T cells to clinical efficacy of PD-L1/PD-1 blockade therapies.The developments undertaken at DIACCURATE to boost CD4 T cells functionality could represent a major step towards improving immunotherapy.”
Prof. Christoph HUBER, co-founder of the mRNA vaccine pioneer BioNTech, board member of the International Association of Cancer Immunotherapy and member of DIACCURATE’s SAB , added: “As we have seen once again with the COVID-19 pandemic, vaccines are an unvaluable immunotherapy tool to prevent and treat diseases that affect the immune system. It has been well known for over a century in the field of infectious diseases, it is also becoming an evidence in the field of oncology, and strategies like that of DIACCURATE that potentiate CD4 T cells response are expected to further improve the efficacy and the profile of vaccines”.
Dr. Bernard MALISSEN, Founder and Director of the Center for Immunophenomics, team leader and former Director of the Centre d'Immunologie de Marseille Luminy and member of DIACCURATE’s SAB , concluded: “Intricate biological networks control physiological and pathologic processes and revolve around biological switches. By integrating incoming signals and determining the downstream pathways that need to be activated, they constitute key “decision makers”. DIACCURATE has laid solid foundations to take on the challenge of targeting such biological switches, which are of tremendous importance in various pathological contexts, including cancer and infectious diseases”.
DIACCURATE
DIACCURATE is a late preclinical stage biotechnology company that invests the new frontiers of immunotherapy and oncology, firstly CD4 immunotherapy and targeted chemotherapy. At the forefront of translational medicine, these sole-in-class drug candidates target incurable diseases: refractory acute myeloid leukemia, pancreatic cancer and AIDS. DIACCURATE is conducting 3 proprietary development programs and expects to start its first clinical trial by 2022.
DIACCURATE is supported by a high-level management team led by Dr. Dominique BRIDON and world-class Board of Directors and Scientific Advisory Board chaired by Dr. Philippe POULETTY, CEO of TRUFFLE, and Prof. Tasuku HONJO, 2018 Nobel Prize in Medicine.
For more information, visit www.diaccurate.com and follow @DiaccurateTx
TRUFFLE CAPITAL
Created in 2001, TRUFFLE CAPITAL is an independent European Venture Capital company, specialising in life sciences (MedTech and Biotech) and in breakthrough IT technologies (FinTech and InsurTech). The mission of TRUFFLE CAPITAL is to help the creation and development of young innovating companies, capable of becoming tomorrow’s leaders.
Chaired by Patrick KRON and led by Dr. Philippe POULETTY et Bernard-Louis ROQUES, co-founders and CEOs, TRUFFLE CAPITAL has raised over €1.1 billion since its inception and helped over 70 companies in the digital technology and life sciences sectors. In 2019, TRUFFLE CAPITAL announced having raised almost €400 million in new institutional funds, including €250 million for new BioMedTech investments.
For more information, visit www.truffle.com and follow @trufflecapital
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005604/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina17.9.2025 14:30:00 CEST | Press release
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced the opening of a state-of-the-art model development center in Kannapolis, North Carolina. This strategic investment expands the company’s operations and enhances its ability to deliver advanced preclinical oncology models, including patient-derived xenografts (PDX), PDX warm models, PDX-derived organoids (PDXO), and patient-derived organoids (PDO), to meet the evolving needs of pharmaceutical and biotechnology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917864004/en/ Crown Bioscience celebrate the official ribbon-cutting ceremony for the company’s new Kannapolis, North Carolina facility, marking an expansion of US oncology model development and preclinical CRO services. The new facility strengthens Crown Bioscience’s US-based capabil
SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 14:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 14:00:00 CEST | Press release
IND clearance marks second study accepted for RLS-1496, a first-in-class disease-modifying selective GPX4 modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process through ferroptosis Results from first RLS-1496 study in patients with psoriasis, atopic dermatitis, and skin aging are expected in Q4 2025; the actinic keratosis Phase 1b/2a study will begin in Q4 2025 Rubedo Clinical Advisory Board expands to include globally renowned dermatologist and immunologist Emma Guttman-Yassky, MD, PhD., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 14:00:00 CEST | Press release
Universal Surveillance Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to Improve Patient Outcomes and Save Lives – Also Projected to Yield Significant Cost Savings Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 14:00:00 CEST | Press release
Four-year data show nearly 9 in 10 RMS patients remained free from progression independent of relapse activity (PIRA)Results highlight the potential of MAVENCLAD to reduce neurodegeneration and neuroinflammation beyond established clinical efficacy outcomes in RMSEvidence suggests that MAVENCLAD effectiveness could be driven by peripheral and central effects without requiring continuous immunosuppression Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom